 WALTHAM, Mass.--BUSINESS WIRE--La Jolla Pharmaceutical Company Nasdaq: LJPC, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress. Corporate Progress Operating Cash Flow Improved: La Jollas net cash provided by used for operating activities for the three months ended March 